Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04328948

A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC

This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve esophagus without compromising overall survival.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

National Cancer Center Hospital

Tokyo, Japan

Location status: Recruiting

Location contact

Ken Kato, M.D./Ph.D

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven squamous cell carcinoma, adenosquamous carcinoma, or basaloid cell carcinoma.
  • All lesions located in the thoracic esophagus. Secondary lesions with an absolute indication for endoscopic resection (EMR/ESD) may not be confined to the thoracic esophagus.
  • Clinical N0M0 with cervical to abdominal contrast-enhanced CT.
  • The deepest lesion is diagnosed as cT1b (SM1 / SM2 / SM3) with upper gastrointestinal endoscopy. If it is difficult to differentiate cT1a-MM and cT1b-SM1 clinically, the wall depth is diagnosed as cT1b-SM1.
  • Aged 20 years and older.
  • ECOG Performance status 0 or 1.
  • No previous therapy against esophageal cancer except for complete resection by EMR/ESD with either pT1a-LPM (pM2) / pT1a-MM (M3) disease or pT1a-MM (M3) disease without vascular infiltration.
  • No history of radiotherapy for the neck, chest, and upper abdomen for any cancers. No chemotherapy or hormone therapy with less than 3 years of disease-free interval for any cancers.
  • Major organ function is preserved. 1) WBC<=12,000/mm3 2) ANC>=1,500/mm3 3) Hb>=10.0 g /dL 4) PLT>=10,000/mm3 5) T-bil<=1.5 mg /dL 6) AST<=100 IU/L 7) ALT<=100 IU/L 8) SpO2>=95% 9) Ccr>=60 mL/min
  • Patients do not have a preference to receive a surgical resection as an initial therapy after receiving explanations.
  • Written informed consent is obtained.

Exclusion criteria

  • Simultaneous or metachronous (within 5 years) double cancers, except for intramucosal tumor curable with local therapy.
  • Active infection requiring systemic therapy.
  • Fever over 38 degrees Celsius
  • Female during pregnancy, within 28 days of post parturition, or during lactation. Male who wants a partner's pregnancy.
  • Psychological disorder, which is difficult to participate in this clinical study.
  • Receiving continuous systemic corticosteroid or immunosuppressant treatment.
  • Positive for HBs antigen or HIV antigen.
  • Diabetes mellitus, which is uncontrollable with continuous use of insulin or hypoglycemic agents.
  • Uncontrolled arterial hypertension.
  • History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration.
  • Uncontrolled valvular disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy.
  • Severe emphysema, interstitial pneumonia or pulmonary fibrosis based on chest CT.
  • With a history of cerebrovascular disorder within 6 months.
  • Drug allergy for iodic drugs.

Treatment and study plan

Chemoradiotherapy

Radiation

Chemoradiotherapy

Primary outcomes

  1. Major progression-free survival

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    If the remnant lesion in the esophagus or a recurrent lesion after complete response (CR) can be curatively removed by salvage EMR/ESD, it is not an event, and other progressions and deaths are events.

Secondary outcomes

  1. Overall survival

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    From date of randomization to date of death, approximately 5 years.

  2. Progression-free survival

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    From date of randomization to date of progression or death, whichever occurs first, approximately 5 years.

  3. Complete response rate

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    CR was defined as disappeared primary tumors without the presence of ulceration or malignant cells in biopsy specimens under endoscopy.

  4. Esophagectomy-free survival

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    From date of randomization to date of esophagectomy or death, whichever occurs first, approximately 5 years.

  5. Adverse events

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    Number of participants with treatment-related adverse events during CRT as assessed by CTCAE v4.0

  6. Long term toxicity

    Time frame: The primary analysis will be held 5-years after the last patient was enrolled.

    Number of participants with treatment-related adverse events after termination of CRT as assessed by CTCAE v4.0

Study contacts

Contact information is provided by the study sponsor or research team.

Motoo Nomura, MD/PhD

CONTACT

[email protected]

81335422511

Sponsors and collaborators

Lead sponsor

National Cancer Center, Japan

Other Gov

Registry information

Official study title

A Randomized Controlled Phase III Trial of Comparing Local Field With Additional Prophylactic Irradiation in Chemoradiotherapy for Clinical-T1bN0M0 Esophageal Cancer

Acronym: ARMADILLO

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Apr 1, 2020
Registry last updated
May 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.